HIV-1-infection — Latent HIV-1, Viral Suppress and Hope for HIV Cure
Citation(s)
Ajose O, Mookerjee S, Mills EJ, Boulle A, Ford N Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. AIDS. 2012 May 15;26(8):929-38. doi: 10.1097/QAD.0b013e328351f5b2.
Dahabieh MS, Battivelli E, Verdin E Understanding HIV latency: the road to an HIV cure. Annu Rev Med. 2015;66:407-21. doi: 10.1146/annurev-med-092112-152941. Review.
Dow DE, Shayo AM, Cunningham CK, Reddy EA Durability of antiretroviral therapy and predictors of virologic failure among perinatally HIV-infected children in Tanzania: a four-year follow-up. BMC Infect Dis. 2014 Nov 7;14:567. doi: 10.1186/s12879-014-0567-3.
Fox MP, Ive P, Long L, Maskew M, Sanne I High rates of survival, immune reconstitution, and virologic suppression on second-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr. 2010 Apr 1;53(4):500-6. doi: 10.1097/QAI.0b013e3181bcdac1.
G Meintjes, G. Maartens, A. Boulle, F. Conradie, E. Goemaere, and E. Hefer, "Adult antiretroviral therapy guideline.," South Afr J HIV Med, vol. 15, no. 4, pp. 121-143, 2014.
Rosenbloom DI, Elliott O, Hill AL, Henrich TJ, Siliciano JM, Siliciano RF Designing and Interpreting Limiting Dilution Assays: General Principles and Applications to the Latent Reservoir for Human Immunodeficiency Virus-1. Open Forum Infect Dis. 2015 Aug 26;2(4):ofv123. doi: 10.1093/ofid/ofv123. eCollection 2015 Dec. Review.
Siliciano JD, Siliciano RF Enhanced culture assay for detection and quantitation of latently infected, resting CD4+ T-cells carrying replication-competent virus in HIV-1-infected individuals. Methods Mol Biol. 2005;304:3-15.
Investigation of the Impact of Inducible, Replication-competent Latent HIV-1 as an Impediment to HIV/AIDS Cure in the Context of Sustained Viral Suppression
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
